Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.
Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator.
复制标题
通过早期输注重组组织型纤溶酶原激活剂来限制心肌梗塞。
作者：
M. O'Rourke;D. Baron;A. Keogh;R. Kelly;G. Nelson;C. Barnes;J. Raftos;K. Graham;K. Hillman;H. Newman
在一项涉及悉尼五家医院和城市救护车辅助医疗服务的双盲随机试验中，145名首次发生心肌梗死且疼痛发作时间小于2.5小时（平均1.9 +/- 0.5 [SD]）的患者被分配到静脉输注100 mg重组组织型纤溶酶原激活剂（rt-PA）或安慰剂超过3小时。进入时的群体是相似的。21天后评估时，rt-PA组左心室射血分数通过对比和放射性核素心室造影测量均高于安慰剂组（61 +/- 13%,n = 64, vs 54 +/- 14%, n = 62，对比，2p = 0.006; 52 +/- 13%, n = 66, vs 48 +/- 13%, n = 62同位素，2p = 0.08）。这表明rt-PA对心肌梗死的限制。
In a double-blind randomized trial involving five Sydney hospitals and the city ambulance paramedical service, 145 patients with a first evolving myocardial infarction and with onset of pain less than 2.5 (mean 1.9 +/- 0.5 [SD]) hr previously were allocated to intravenous infusion of 100 mg recombinant tissue-type plasminogen activator (rt-PA) or placebo over 3 hr. The groups at entry were similar. At assessment 21 days later, left ventricular ejection fraction measured both by contrast and radionuclide ventriculography was higher in the rt-PA compared with the placebo group (61 +/- 13%, n = 64, vs 54 +/- 14%, n = 62, contrast, 2p = .006; 52 +/- 13%, n = 66, vs 48 +/- 13%, n = 62 isotope, 2p = .08). This indicates limitation of myocardial infarction by rt-PA.